ZA200505389B - A method of treating a malignancy in a subject viadirect picornaviral-medicated oncolysis - Google Patents
A method of treating a malignancy in a subject viadirect picornaviral-medicated oncolysis Download PDFInfo
- Publication number
- ZA200505389B ZA200505389B ZA200505389A ZA200505389A ZA200505389B ZA 200505389 B ZA200505389 B ZA 200505389B ZA 200505389 A ZA200505389 A ZA 200505389A ZA 200505389 A ZA200505389 A ZA 200505389A ZA 200505389 B ZA200505389 B ZA 200505389B
- Authority
- ZA
- South Africa
- Prior art keywords
- virus
- cells
- cancer
- mammal
- echovirus
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 81
- 206010028980 Neoplasm Diseases 0.000 title claims description 78
- 201000011510 cancer Diseases 0.000 title claims description 49
- 230000036210 malignancy Effects 0.000 title description 13
- 210000004027 cell Anatomy 0.000 claims description 400
- 241001466953 Echovirus Species 0.000 claims description 211
- 241000700605 Viruses Species 0.000 claims description 201
- 206010033128 Ovarian cancer Diseases 0.000 claims description 98
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 95
- 230000002159 abnormal effect Effects 0.000 claims description 84
- 208000015181 infectious disease Diseases 0.000 claims description 71
- 241000124008 Mammalia Species 0.000 claims description 57
- 230000014509 gene expression Effects 0.000 claims description 50
- 238000011282 treatment Methods 0.000 claims description 47
- 201000001441 melanoma Diseases 0.000 claims description 37
- 239000002054 inoculum Substances 0.000 claims description 32
- 206010009944 Colon cancer Diseases 0.000 claims description 26
- 206010006187 Breast cancer Diseases 0.000 claims description 24
- 208000026310 Breast neoplasm Diseases 0.000 claims description 24
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 23
- 230000009089 cytolysis Effects 0.000 claims description 19
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 16
- 206010060862 Prostate cancer Diseases 0.000 claims description 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 16
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 15
- 230000034994 death Effects 0.000 claims description 15
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 15
- 201000002528 pancreatic cancer Diseases 0.000 claims description 15
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 208000029742 colonic neoplasm Diseases 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 10
- 241000709687 Coxsackievirus Species 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 5
- 230000030833 cell death Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 31
- 108020003175 receptors Proteins 0.000 description 31
- 230000003612 virological effect Effects 0.000 description 29
- 230000002101 lytic effect Effects 0.000 description 28
- 230000027455 binding Effects 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
- 108010044426 integrins Proteins 0.000 description 21
- 102000006495 integrins Human genes 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 241000709698 Coxsackievirus A21 Species 0.000 description 18
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- 241000709675 Coxsackievirus B3 Species 0.000 description 17
- 230000002611 ovarian Effects 0.000 description 17
- 241000709701 Human poliovirus 1 Species 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 15
- 230000003211 malignant effect Effects 0.000 description 15
- 241000709661 Enterovirus Species 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 206010003445 Ascites Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 239000013553 cell monolayer Substances 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 230000000174 oncolytic effect Effects 0.000 description 9
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 9
- 102000012422 Collagen Type I Human genes 0.000 description 8
- 108010022452 Collagen Type I Proteins 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 206010057248 Cell death Diseases 0.000 description 7
- 238000011579 SCID mouse model Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 210000005170 neoplastic cell Anatomy 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 244000309459 oncolytic virus Species 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241000991587 Enterovirus C Species 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000702263 Reovirus sp. Species 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000005567 liquid scintillation counting Methods 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 4
- 229960000471 pleconaril Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- 241000711404 Avian avulavirus 1 Species 0.000 description 3
- 102000036365 BRCA1 Human genes 0.000 description 3
- 108700020463 BRCA1 Proteins 0.000 description 3
- 101150072950 BRCA1 gene Proteins 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000204855 Echovirus E1 Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100029740 Poliovirus receptor Human genes 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 206010060931 Adenovirus infection Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010048623 Collagen Receptors Proteins 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037828 epithelial carcinoma Diseases 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- BJOZNDRNJJZHPZ-LUWBGTNYSA-N 9-O-acetylneuraminic acid Chemical compound CC(=O)OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1N BJOZNDRNJJZHPZ-LUWBGTNYSA-N 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 206010004433 Benign ovarian tumour Diseases 0.000 description 1
- 102000007269 CA-125 Antigen Human genes 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 101710143772 Complement receptor type 2 Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 101000936738 Coturnix japonica Astacin-like metalloendopeptidase Proteins 0.000 description 1
- 241000146307 Coxsackievirus A13 Species 0.000 description 1
- 241000146310 Coxsackievirus A15 Species 0.000 description 1
- 241000146301 Coxsackievirus A18 Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000988559 Enterovirus A Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014978 Epidemic pleurodynia Diseases 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000701135 Human adenovirus D9 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000699727 Human echovirus Species 0.000 description 1
- 241000709716 Human enterovirus 70 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 241000709704 Human poliovirus 2 Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 108010072255 Integrin alpha3beta1 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 101000794562 Naegleria gruberi Calmodulin, flagellar Proteins 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 206010035623 Pleuritic pain Diseases 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001044 anti-enteroviral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002236 cellular spheroid Anatomy 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000011500 cytoreductive surgery Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 201000008016 ovarian benign neoplasm Diseases 0.000 description 1
- 208000016632 ovarian clear cell cancer Diseases 0.000 description 1
- 201000003707 ovarian clear cell carcinoma Diseases 0.000 description 1
- 201000003733 ovarian melanoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000002023 papillomaviral effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000002524 peritoneal carcinoma Diseases 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 108010048507 poliovirus receptor Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000012808 pre-inoculation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011539 total abdominal hysterectomy Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000019930 undifferentiated ovarian carcinoma Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000007919 viral pathogenicity Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002953436A AU2002953436A0 (en) | 2002-12-18 | 2002-12-18 | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200505389B true ZA200505389B (en) | 2006-09-27 |
Family
ID=30004521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200505389A ZA200505389B (en) | 2002-12-18 | 2003-12-18 | A method of treating a malignancy in a subject viadirect picornaviral-medicated oncolysis |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7485292B2 (enExample) |
| EP (1) | EP1581257B1 (enExample) |
| JP (2) | JP2006517189A (enExample) |
| KR (1) | KR101171295B1 (enExample) |
| CN (2) | CN102166228B (enExample) |
| AU (1) | AU2002953436A0 (enExample) |
| CA (1) | CA2510227C (enExample) |
| ES (1) | ES2463678T3 (enExample) |
| NZ (1) | NZ541230A (enExample) |
| WO (1) | WO2004054613A1 (enExample) |
| ZA (1) | ZA200505389B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US8236298B2 (en) | 2004-08-20 | 2012-08-07 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
| WO2006074526A1 (en) * | 2005-01-17 | 2006-07-20 | Viralytics Limited | Method and composition for treatment of neoplasms |
| US9566307B2 (en) | 2012-04-19 | 2017-02-14 | Kyushu University, National University Corporation | Pharmaceutical composition |
| ES2566146T3 (es) * | 2013-07-16 | 2016-04-11 | Sia Latima | Virus de ARN oncolítico genéticamente estable, método de fabricación y uso del mismo |
| WO2015080631A1 (en) * | 2013-11-27 | 2015-06-04 | Obschestvo S Ogranichennoy Otvetstvennost`Yu "Panacela Labs" | Improved expression vector for toll-like receptor and agonist and use for treating cancer |
| US20170000832A1 (en) | 2014-02-27 | 2017-01-05 | Viralytics Limited | Combination method for treatment of cancer |
| CN103981152B (zh) * | 2014-04-16 | 2015-01-21 | 武汉博威德生物技术有限公司 | 一种柯萨奇病毒及其制备抗肿瘤药物之应用 |
| AU2017335673B2 (en) | 2016-09-27 | 2024-11-14 | Sator Therapeutics LLC | Optimized oncolytic viruses and uses thereof |
| EP3610870A4 (en) * | 2017-03-31 | 2020-12-09 | Ogata, Hisanobu | METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT |
| CN109419818B (zh) * | 2017-08-24 | 2021-08-10 | 厦门大学 | 一种用于治疗肿瘤的埃可病毒 |
| CN107669707A (zh) * | 2017-11-16 | 2018-02-09 | 邹罡 | 埃可病毒作为溶瘤病毒在抗肿瘤中的应用 |
| MX2021005448A (es) * | 2018-11-13 | 2021-08-11 | Oncorus Inc | Polinucleotidos encapsulados y metodos de uso. |
| US20240299540A1 (en) | 2021-02-05 | 2024-09-12 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54113421A (en) * | 1978-02-24 | 1979-09-05 | Fumiaki Taguchi | Large scale cultivation of virus |
| US5585254A (en) | 1987-08-21 | 1996-12-17 | University Of Colorado Foundation, Inc. | Autonomous parvovirus gene delivery vehicles and expression vectors |
| EP0466815A4 (en) | 1989-04-05 | 1992-09-02 | Novacell Corpporation | Infectious targetted replication-defective virion |
| CA2051289C (en) | 1990-09-14 | 2002-11-26 | Robert L. Martuza | Viral mediated destruction of neoplastic cells |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| AU2252092A (en) | 1991-06-24 | 1993-01-25 | Research Foundation Of The State University Of New York, The | De novo cell-free synthesis of picornavirus |
| JPH06509578A (ja) | 1991-07-26 | 1994-10-27 | ユニバーシティ・オブ・ロチェスター | 悪性細胞利用による癌治療法 |
| US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
| SE503225C2 (sv) | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| PT931830E (pt) | 1993-02-16 | 2001-08-30 | Onyx Pharma Inc | Virus citopaticos para terapia e profilaxia de neoplasia |
| PT1486211E (pt) | 1993-04-30 | 2009-02-02 | Wellstat Biologics Corp | Composições para tratamento do cancro utilizando vírus |
| US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5688773A (en) | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
| US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
| US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| CA2323067A1 (en) | 1998-03-12 | 1999-09-16 | The Trustees Of The University Of Pennsylvania | Producer cells for replication selective viruses in the treatment of malignancy |
| US6060316A (en) | 1998-06-09 | 2000-05-09 | President And Fellows Of Harvard College | Methods of targeting of viral entry |
| US6264940B1 (en) | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
| WO2000045853A2 (en) | 1999-02-05 | 2000-08-10 | Arch Development Corporation | Treatment of tumors with genetically engineered herpes virus |
| AU4246900A (en) | 1999-04-15 | 2000-11-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| AU2005201079C1 (en) | 1999-04-15 | 2008-11-06 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| EP1067188A1 (en) | 1999-07-08 | 2001-01-10 | Introgene B.V. | Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR) |
| DE19939095A1 (de) | 1999-08-18 | 2001-02-22 | Univ Eberhard Karls | Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer |
| NZ523805A (en) | 1999-09-17 | 2004-09-24 | Pro Virus Inc | Oncolytic virus |
| MXPA02004736A (es) | 1999-11-12 | 2003-01-28 | Oncolytics Biotech Inc | Virus para el tratamiento de trastornos proliferativos celulares. |
| US7001596B1 (en) | 1999-11-15 | 2006-02-21 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| AU2004202292B2 (en) | 1999-11-25 | 2007-06-14 | Viralytics Limited | Method of Treating a Malignancy in a Subject |
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU770517B2 (en) | 1999-11-25 | 2004-02-26 | Viralytics Limited | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| KR100802403B1 (ko) | 2000-01-21 | 2008-02-13 | 바이오벡스 리미티드 | 바이러스 주 |
| CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| AU6814601A (en) | 2000-06-01 | 2001-12-11 | Sloan Kettering Inst Cancer | Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| WO2002043647A2 (en) | 2000-12-01 | 2002-06-06 | University Of Ottawa | Oncolytic virus |
| WO2002092132A2 (en) * | 2001-01-05 | 2002-11-21 | Corixa Corporation | Microparticles and methods for delivery of recombinant viral vaccines |
| WO2002087625A1 (en) | 2001-05-02 | 2002-11-07 | Ramot At Tel-Aviv University Ltd. | Composite oncolytic herpes virus vectors |
| EP2140879A1 (en) | 2001-05-09 | 2010-01-06 | M'S Science Corporation | Composition and method for treating cancer using herpes virus |
| DE60239394D1 (de) | 2001-05-11 | 2011-04-21 | Wellstat Biologics Corp | Onkolytische virustherapie |
| CA2352439A1 (en) | 2001-07-17 | 2003-01-17 | Patrick W. K. Lee | Engineering oncolytic viruses |
| JP2004536607A (ja) | 2001-07-23 | 2004-12-09 | オニックス ファーマシューティカルズ，インコーポレイティド | 標的化されたヒト癌細胞において選択的に複製するウイルス変異体 |
| JP2005519091A (ja) | 2002-03-01 | 2005-06-30 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 癌の再発及び転移の予防 |
| AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| WO2003092579A2 (en) | 2002-04-29 | 2003-11-13 | Hadasit Medical Research Services And Development Company Ltd. | Compositions and methods for treating cancer with an oncolytic viral agent |
| MXPA04011007A (es) | 2002-05-09 | 2005-02-14 | Oncolytics Biotech Inc | Metodo para reducir el dolor usando virus oncoliticos. |
| AU2002953436A0 (en) * | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US20050019308A1 (en) | 2003-07-07 | 2005-01-27 | Oncolytics Biotech Inc. | Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac |
| US20070036758A1 (en) | 2003-07-08 | 2007-02-15 | Bertram Jacobs | Mutants of vaccinia virus as oncolytic agents |
| AU2004275832A1 (en) | 2003-09-26 | 2005-04-07 | Novartis Ag | Seneca Valley virus based compositions and methods for treating disease |
| KR20060131975A (ko) | 2004-03-11 | 2006-12-20 | 바이로타르그 피티와이 엘티디 | 변형된 종양 용해 바이러스 |
| WO2005107474A2 (en) | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| US8080240B2 (en) | 2004-10-21 | 2011-12-20 | The Penn State Research Foundation | Parvovirus methods and compositions for killing neoplastic cells |
-
2002
- 2002-12-18 AU AU2002953436A patent/AU2002953436A0/en not_active Abandoned
-
2003
- 2003-12-18 CA CA2510227A patent/CA2510227C/en not_active Expired - Fee Related
- 2003-12-18 EP EP03779569.7A patent/EP1581257B1/en not_active Expired - Lifetime
- 2003-12-18 US US10/539,219 patent/US7485292B2/en not_active Expired - Lifetime
- 2003-12-18 ZA ZA200505389A patent/ZA200505389B/en unknown
- 2003-12-18 JP JP2004559490A patent/JP2006517189A/ja active Pending
- 2003-12-18 KR KR1020057011510A patent/KR101171295B1/ko not_active Expired - Fee Related
- 2003-12-18 NZ NZ541230A patent/NZ541230A/en not_active IP Right Cessation
- 2003-12-18 ES ES03779569.7T patent/ES2463678T3/es not_active Expired - Lifetime
- 2003-12-18 WO PCT/AU2003/001688 patent/WO2004054613A1/en not_active Ceased
- 2003-12-18 CN CN201110091011.1A patent/CN102166228B/zh not_active Expired - Fee Related
- 2003-12-18 CN CN2003801098083A patent/CN1784242B/zh not_active Expired - Fee Related
-
2009
- 2009-02-03 US US12/365,120 patent/US20100062020A1/en not_active Abandoned
-
2011
- 2011-07-08 JP JP2011151340A patent/JP2012046489A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20100062020A1 (en) | 2010-03-11 |
| CN102166228A (zh) | 2011-08-31 |
| CN102166228B (zh) | 2014-02-19 |
| EP1581257B1 (en) | 2014-04-30 |
| US7485292B2 (en) | 2009-02-03 |
| US20060134778A1 (en) | 2006-06-22 |
| KR20050115859A (ko) | 2005-12-08 |
| EP1581257A1 (en) | 2005-10-05 |
| HK1082194A1 (en) | 2006-06-02 |
| CA2510227A1 (en) | 2004-07-01 |
| JP2012046489A (ja) | 2012-03-08 |
| AU2002953436A0 (en) | 2003-01-09 |
| CN1784242A (zh) | 2006-06-07 |
| NZ541230A (en) | 2008-04-30 |
| ES2463678T3 (es) | 2014-05-28 |
| CN1784242B (zh) | 2011-06-08 |
| JP2006517189A (ja) | 2006-07-20 |
| EP1581257A4 (en) | 2007-10-17 |
| KR101171295B1 (ko) | 2012-08-07 |
| WO2004054613A1 (en) | 2004-07-01 |
| HK1157657A1 (en) | 2012-07-06 |
| CA2510227C (en) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100062020A1 (en) | Method of Treating a Malignancy in a Subject Via Direct Picornaviral-Mediated Oncolysis | |
| Au et al. | Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21 | |
| US8722036B2 (en) | Methods for treating malignancies using coxsackieviruses | |
| Shafren et al. | Oncolysis of human ovarian cancers by echovirus type 1 | |
| Berry et al. | Potent oncolytic activity of human enteroviruses against human prostate cancer | |
| CN101027394A (zh) | 修饰的溶瘤病毒 | |
| CN101132798B (zh) | 核酸分子在制备用于治疗黑色素瘤的药物中的应用及其组合物 | |
| AU2003287773B2 (en) | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis | |
| HK1082194B (en) | Composition comprising echovirus ev1 and its use | |
| HK1157657B (en) | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis | |
| AU1681601A (en) | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same | |
| Wilcox | OF SCIENCE DEGREE | |
| AU2015230743A1 (en) | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same | |
| AU2007211890A1 (en) | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |